Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis.
about
Perfluorocarbon nanoparticles: evolution of a multimodality and multifunctional imaging agent.Phase transitions of nanoemulsions using ultrasound: experimental observations.Phase-shift, stimuli-responsive perfluorocarbon nanodroplets for drug delivery to cancer.Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsionsMolecular Imaging of Acute Cardiac Transplant Rejection: Animal Experiments and Prospects.Perfluorocarbon nanoemulsions with fluorescent, colloidal and magnetic propertiesPost-formulation peptide drug loading of nanostructures for metered control of NF-κB signalingDissecting the mechanism of carotid atherosclerosis from the perspective of regulationMacrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases.A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy.Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis.Nanotherapeutic approaches for the treatment of rheumatoid arthritis.Emerging role of radiolabeled nanoparticles as an effective diagnostic technique.Molecular magnetic resonance imaging of atherosclerotic vessel wall disease.Molecular Cardiovascular Magnetic Resonance: Current Status and Future Prospects.Research Spotlight: Functionalized nanoparticles for future cardiovascular medicine.High sensitivity 19F MRI of a perfluorooctyl bromide emulsion: application to a dynamic biodistribution study and oxygen tension mapping in the mouse liver and spleen.
P2860
Q30434964-13CDF132-D21F-4C32-974A-805ABE71BC76Q30450112-95E32F84-C490-4191-9A68-2C82B3451701Q30450131-F821F6BE-BBE2-4D4D-BBF2-EF21483D77C3Q30465710-29637B5D-9EB9-4576-818A-0736CB144F86Q30491760-0470F251-1B69-4F73-A776-F3D1E5B860E5Q33760320-50D369BA-E7AE-4647-82E2-CEFE43B172E0Q34381627-27C2D67D-AC47-473B-B18D-35D0F1F2FDB7Q34426836-D39CCCD2-4633-404A-A364-6AC0328AF3F5Q34785236-16074ED6-964C-4C0F-8B0C-CA935EB86483Q36335331-DBD102AE-2AE6-4A81-A74D-087AD07C3AFAQ37730633-155A2135-45E1-46BB-A374-C8AE83569673Q37916426-B4988E8A-8A2A-4F57-BD0C-04B085755B66Q38027231-C64D51B5-CE91-4388-B6FC-4F734FB91AC3Q38542308-8E830380-0F0F-4652-9A2A-22C61DC86DC5Q38796404-D378F2E9-183B-426A-9322-E15780A3D61CQ39315471-B048EFB5-BCDC-465D-8555-AAFDDDEC1C53Q45243987-7428123B-D53E-4939-9AE3-3ED18A3BF878
P2860
Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-angiogenic perfluorocarbo ...... treatment of atherosclerosis.
@en
Anti-angiogenic perfluorocarbo ...... treatment of atherosclerosis.
@nl
type
label
Anti-angiogenic perfluorocarbo ...... treatment of atherosclerosis.
@en
Anti-angiogenic perfluorocarbo ...... treatment of atherosclerosis.
@nl
prefLabel
Anti-angiogenic perfluorocarbo ...... treatment of atherosclerosis.
@en
Anti-angiogenic perfluorocarbo ...... treatment of atherosclerosis.
@nl
P2093
P2860
P921
P356
P1476
Anti-angiogenic perfluorocarbo ...... treatment of atherosclerosis.
@en
P2093
Gregory M Lanza
Patrick M Winter
Samuel A Wickline
Shelton D Caruthers
Tillmann Cyrus
P2860
P304
P356
10.1002/WNAN.9
P577
2009-05-01T00:00:00Z